Postdoctoral Fellows and Research Associates

The Faltas Lab at Weill Cornell Medicine, situated in the heart of New York City, invites exceptional scientists to join our pioneering team as postdoctoral fellows and research associates. We’re breaking new ground in cancer biology, with important discoveries recently published in Nature (Nguyen et al. 2024) and featured on the cover.

Our mission is to investigate biological processes that drive cancer evolution to revolutionize treatment approaches. We’re decoding the complexities of intra-tumor heterogeneity and unraveling the mechanisms behind drug resistance and metastasis. Our innovative approach combines state-of-the-art experimental models – from patient-derived organoids to advanced animal models – with cutting-edge computational biology techniques.

Our research excellence is supported by substantial, long-term funding, including a prestigious NCI R37 MERIT award (secured for the next 7 years), Department of Defense grants, the American Cancer Society, Starr Cancer Consortium grants, and multiple other sources. This robust funding ensures our scientists can pursue bold ideas.

Beyond competitive salaries (exceeding standard NIH postdoctoral stipends), Weill Cornell Medicine offers an exceptional benefits package, including comprehensive health, dental, and vision insurance, plus subsidized housing in one of the world’s most exciting cities. Under Dr. Faltas’s mentorship, you’ll thrive in a diverse, collaborative environment designed to launch the next generation of scientific leaders.

Ongoing and future projects in the lab include:

1. Investigating the role of APOBEC3 cytidine deaminase mutagenic enzymes in driving intra-tumor heterogeneity and the biological function of APOBEC3-induced mutations and RNA-editing.
2. Investigating the role of structural variants, such as extrachromosomal DNA, in the evolution of therapy resistance.
3. Investigating the biogenesis and persistence of ecDNA in treatment resistance.
4. Investigating the role of non-coding genome in cancer evolution.
5. Bio-Digital Avatars for Personalized Sequencing of Bladder Cancer Therapies.
6. Translational projects leveraging our findings for personalized therapy and drug development for patients with urothelial and other cancers.

Ideal candidates:

• Ph.D. in molecular biology, cell biology, biochemistry, pharmacology, or related fields with a background in cancer biology. Excellent skills in basic molecular biology and biochemical techniques, including cloning, SDS-PAGE western blotting, qPCR, functional assays, and mammalian cell culture.
• Experience in mouse handling and experiments, such as tumor xenograft models and tail vein injections, is a plus.
• Familiarity with basic R or Python is a plus but not required.
• Excellent communication, organizational, and problem-solving skills.
• Track record of productivity (publications) from Ph.D.

Interested applicants are encouraged to send their CV, a statement of research interests, copies of previous publications, and names and contact information of three references to Dr. Bishoy M. Faltas, before the application deadline.